Lead Product(s): RX-5902
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Rexahn Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 09, 2020
The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.